Theravance Biopharma (TBPH) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.18

Estimate

$0.07

Surprise

+161.7%

Score at report (before → after)

5.8 → 5.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Theravance Biopharma (TBPH) beat the $0.07 estimate with diluted EPS of $0.18 — a large 161.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.8/10 after the report.

TrendMatrix currently rates TBPH Sell at 4.8/10.

3 of the last 4 quarters beat the estimate; this quarter's +161.7% surprise compares with a +335.6% four-quarter average. Next scheduled report: 2026-11-10.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$17.01

Price target

$19.56

Stop

$16.91

Upside to target

+15.0%

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$883.1M

P/E (fwd)

13.3

P/E (ttm)

16.4

52-week range

$13.08–$21.03

Off 52-week high

19.1%

RSI (14)

69

Volume vs avg

1.41×

Score today

4.8/10